Back

Daewoong, Jeil and HK inno.N expand from P-CAB drugs into diabetes

Verifying
  • Daewoong Pharmaceutical, Jeil Pharmaceutical and HK inno.N are expanding into diabetes treatments.
  • 145.7%: Envlo’s second-quarter outpatient prescriptions increased year-on-year to 7.2 billion won.
  • HK inno.N is running separate Phase 3 trials for diabetes and obesity.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.